PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Align Technology, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from Align Technology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Debt Due Cover Ratio: Debt due within a year is covered 18.6 times by its yearly operating cash. Higher than 89% of Healthcare companies in United States.
  • Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 5.4 times. Higher than 88% of Healthcare companies in United States.

Cash quality

Profit Cash Ratio

$166

Over the last 3 years, every $100 of reported profit came with $166 of operating cash.

Higher than 63% of Healthcare companies in United States.

Self-Funding Ratio

5.4×

Over the last 3 years its own operating cash covered its investment spending (capex) 5.4 times.

Higher than 88% of Healthcare companies in United States.

Cash Locked Ratio

$30

For every $100 of sales, $30 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier.

More money tied up than 67% of Healthcare companies in United States.

Growth quality

Steadiness Ratio

3/3 · 1/3

Sales grew in 3 of the last 3 years; profit grew in 1 of 3.

Steadier than 69% of Healthcare companies in United States.

Growth Efficiency Ratio

$16

Sales grew 8% in 3 years; of every extra $100 of sales, $16 became extra profit.

Lower than 54% of Healthcare companies in United States.

Asset Productivity Ratio

+8% / +5%

In 3 years sales changed by +8% while total assets changed by +5%. Both moved at about the same pace.

Balance-sheet strength

Debt Due Cover Ratio

18.6×

Debt due within a year is covered 18.6 times by its yearly operating cash.

Higher than 89% of Healthcare companies in United States.

Cash Cushion Ratio

+9%

Cash, after subtracting all debt, equals 9% of its market value (net cash).

Higher than 50% of Healthcare companies in United States.

Tangible Assets Ratio

91%

Of every $100 the company owns, $91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.

More tangible than 63% of Healthcare companies in United States.

Tangible Net Worth Ratio

86%

Of every $100 of net worth, $86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.

More tangible than 66% of Healthcare companies in United States.

Shareholders

Shareholder Slice Ratio

−8%

Share count fell 8% in 3 years (buybacks), so each share's slice of the company became larger.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (13)

Align Technology, Inc. owes $0.34 for every $1 it owns. Net profit fell 3% in the year to Dec 2025, and grew 4% a year on average over 3 years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

27.0

Investors pay $27.0 for every $1 of Align Technology, Inc.'s yearly profit, higher than 50% of Healthcare companies in United States.

P/B ratio

2.61

The share price is 2.61 times Align Technology, Inc.'s book value per share, higher than 50% of Healthcare companies in United States.

Market cap

$11.0 B

The total market value of all of Align Technology, Inc.'s shares at today's price (share price × number of shares), larger than 91% of Healthcare companies in United States. PosiCap size class: Tito Cap.

Net worth (book value)

$4.2 B

What Align Technology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

$59.58

Net worth divided by the number of shares. The share price of $155.51 is 2.6 times this, which is the P/B above.

Return on equity (ROE)

10.2%

Align Technology, Inc. earned 10.2% on its shareholders' money over the last year, higher than 83% of Healthcare companies in United States.

Owes vs Owns

0.34×

Align Technology, Inc. owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.

Dividend yield

None

Align Technology, Inc. does not currently pay a dividend.

Revenue growth

+1%

Revenue rose 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.

Profit growth

-3%

Net profit fell 3% in the year to Dec 2025, and grew 4% a year on average over 3 years.

Profit margin

10.2%

Align Technology, Inc. keeps $10 of every $100 of revenue as net profit.

Cash quality

1.4×

Cash from Align Technology, Inc.'s business was 1.4× its reported profit in the year to Dec 2025 — its profit turned into cash.

Cash vs debt

Net cash

Align Technology, Inc. held $980 M more cash than debt (net cash) at Dec 2025.

Questions

What is Align Technology, Inc.'s P/E ratio?

Investors pay $27.0 for every $1 of Align Technology, Inc.'s yearly profit, higher than 50% of Healthcare companies in United States.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For Align Technology, Inc.: $11.0 B ÷ $4.2 B (30 Jun 2026) = 2.6.

What is Align Technology, Inc.'s return on equity?

Align Technology, Inc. earned 10.2% on its shareholders' money over the last year, higher than 83% of Healthcare companies in United States.

How much does Align Technology, Inc. owe compared with what it owns?

Align Technology, Inc. owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.

Does Align Technology, Inc. pay a dividend?

No. Align Technology, Inc. does not currently pay a dividend.

Is Align Technology, Inc.'s revenue growing?

Revenue rose 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.